Protalix BioTherapeutics Inc. ’s (PLX) share price has entered into oversold territory with an RSI value of 22.9. The Zacks Consensus Estimate on Protalix BioTherapeutics Inc.’s earnings for the full year period has profit of 0.07 cents over the past two months to $-0.21 per share. Currently, Protalix BioTherapeutics Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (PLX) after its recent drop.
PROTALIX BIOTHERAPEUTICS INC (PLX): Free Stock Analysis Report
Zacks Investment Research
- Health Care Industry
- Finance Trading
- Protalix BioTherapeutics